|
1）Bone RC, Balk RA, Cerra FB, et al. Difinition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American college of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 10; 1644-55
|
|
|
|
|
2）Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38: S26-S34
|
|
|
|
|
3）丸藤 哲，射場敏明，江口 豊，他．急性期DIC診断基準．多施設前向き検討結果報告．日救急医会誌．2005; 16: 188-202
|
|
|
|
|
4）小関一英，土佐亮一，布施 明，他．DIC早期診断基準としての“SIRS-Associated Coagulopathy (SAC)”. バイオメディカル．2004; 14: 19-24
|
|
|
|
|
|
5）丸藤 哲, 射場敏明, 江口 豊, 他．急性期DIC診断基準. 多施設前向き検討結果報告. 日救急医会誌．2005; 16: 188-202
|
|
|
|
|
|
6）Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994: 149; 818-24
|
|
|
|
|
|
7）Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease- activated receptors in a mouse model of endotoxemia. Blood. 2004: l03; 1342-7
|
|
|
|
|
|
8）Ito T, Kawahara K, Nakamura T, et al, High-mobility group box l protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007: 5; 109-16
|
|
|
|
|
|
9）Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Thromb Haemost. 2004; 2: 1924-33
|
|
|
|
|
|
10）Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 4: 90-7
|
|
|
|
|
|
11）Beale R, Reinhart K, Brunkhorst FM, et al. PROGRESS Advisory Board. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection. 2009; 37: 222-32
|
|
|
|
|
|
12）織田成人，相引眞幸，池田寿昭，他．日本集中治療医学会，Sepsis Registry委員会. 日本版敗血症診療ガイドライン. 日集中医誌．2013; 20: 124-73
|
|
|
|
|
|
13）Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign guidelines: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41: 580-637
|
|
|
|
|
|
14）Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012; 18: 891-7
|
|
|
|
|
|
15）Ishikura H, Nishida T, Murai A, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care. 2014; 20: 18, R19
|
|
|
|
|